

A mixed methods protocol to investigate medication adherence in patients with rheumatoid arthritis of White British and South Asian origin

Kanta Kumar,¹ Karim Raza,² Peter Nightingale,³ Rob Horne,⁴ Karen Shaw,¹ Sheila Greenfield,¹ Paramjit Gill¹

To cite: Kumar K, Raza K, Nightingale P, *et al.* A mixed methods protocol to investigate medication adherence in patients with rheumatoid arthritis of White British and South Asian origin. *BMJ Open* 2013;**3**:e001836. doi:10.1136/bmjopen-2012-001836

► Prepublication history for this paper are available online. To view these files please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2012-001836>).

Received 2 August 2012
 Revised 30 November 2012
 Accepted 14 January 2013

This final article is available for use under the terms of the Creative Commons Attribution Non-Commercial 2.0 Licence; see <http://bmjopen.bmj.com>

¹Primary Care, The School of Health and Population Sciences, University of Birmingham, Birmingham, UK

²Department of Rheumatology, The School of Immunity and Infection, University of Birmingham, Birmingham, UK

³Wolfson Building, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK

⁴Centre for Behavioural Medicine, The School of Pharmacy, University of London, London, UK

Correspondence to

Kanta Kumar;
k.kumar@bham.ac.uk

ABSTRACT

Background: Low adherence to medicines is an important issue as up to 40% of patients with chronic diseases do not take their medications as prescribed. This leads to suboptimal clinical benefit. In the context of rheumatoid arthritis, there is a dearth of data on adherence to disease-modifying antirheumatic drugs among minority ethnic groups. This study aims to assess the relationship between adherence to medicines and biopsychosocial variables in patients with rheumatoid arthritis of South Asian and White British origin.

Methods/analysis: A mixed methods approach will be used, encompassing a cross-sectional survey of 176 patients collecting demographic and clinical data, including information on adherence behaviour collected using a series of questionnaires. This will be followed by indepth qualitative interviews.

Ethics and dissemination: This study has been approved by the South Birmingham (10/H1207/89) and Coventry and Warwickshire (12/WM/0041) Research Ethics Committees. The authors will disseminate the findings in peer-reviewed publications.

INTRODUCTION

Rheumatoid arthritis (RA) is a chronic systemic inflammatory disorder that is characterised by joint inflammation¹ and is often associated with a poor quality of life.² The disease lays a huge financial burden on the National Health Service and on individuals as about a third of patients stop work within the first 5 years of diagnosis.³ Recent therapeutic advances now enable effective control of disease in a large proportion of patients.^{4 5} Taking disease-modifying antirheumatic drugs (DMARDs) as prescribed may not only reduce articular disease activity and progression, but it may also reduce the risk of extra-articular features of RA such as cardiovascular disease.⁶ Adherence to medicines is

ARTICLE SUMMARY

Article focus

- This study aims to assess the relationship between adherence to medicines and biopsychosocial variables in patients with rheumatoid arthritis (RA) of South Asian and White British origin.
- Further, the study will explore the reasons underlying high and low adherence among these two ethnic groups.
- Furthermore, this study will provide information for the development of an intervention to change beliefs and behaviours.

Key messages

- Medication adherence is reported to be poor among ethnic population.
- In the context of RA there is a dearth of data on adherence to disease modifying antirheumatic drugs among minority ethnic groups.
- Mixed-methods approach is a useful way to obtain data to help improve medication adherence.

Strengths and limitations of this study

- A key strength of the study is that it will allow an opportunity to further explore issues that arise in phase 1 of the study using qualitative methodologies. The motivational factors that encourage patients to adhere well can be discussed in more detail.
- Potential limitation, however, is that the study design will exclude patients from other backgrounds.

thus likely to be an important determinant of RA treatment success. However, it is estimated that in developed countries, 40% of patients who suffer from chronic diseases do not adhere to treatment recommendations,^{7 8} with adherence rates dropping most dramatically after the first 6 months of therapy.⁹

Efforts to improve treatment outcomes require a better understanding of the particular barriers to and facilitators of adherence to therapy, and of patient experiences of taking

treatment. This is a complex process in which factors associated with non-adherent behaviour can be organised into the following interacting domains: (1) socio-economic factors; (2) health professional and health services-related factors; (3) characteristics of the treatment regimen; (4) characteristics of the disease and (5) patient-related factors.⁸ Furthermore, to better understand patients' medicine taking, many researchers have examined cognitive factors such as patients' perception of their disease, and factors which can be changed to enable more effective behavioural interventions.⁸ Among the different models proposed,^{10 11} Clifford *et al*¹² have developed the Necessity–Concern framework. This framework has been shown to explain non-adherence across a range of illnesses.¹³ According to Horne,^{14 15} patients' motivation to start and to continue with medication is often influenced by the way in which they evaluate their need for treatment. Adherent behaviour depends on which of the two beliefs prevails, that is, the necessity of the medicine or concerns about the possible threat of the medicines.⁷ This can be captured by the two subscales of the Beliefs about Medicines Questionnaire (BMQ):¹⁶ first, the *specific necessity* scale, which largely focuses on assessing the respondents' beliefs about the necessity of their prescribed medication for controlling their illness and maintaining their health (eg, 'my health, at present, depends on my medication'); and second, concerns about the adverse consequences of taking prescribed medication, which mostly focus on assessing the *specific concerns* scale (eg, 'I sometimes worry about the long-term effect of my medication'). Together, the Necessity–Concern Framework model¹² provides a useful framework to study adherence in patients with RA of South Asian and White British origin.

Several studies have reported that higher levels of self-efficacy and social support are associated with improved medication adherence,¹⁷ although there are conflicting data.¹⁸ Other factors may be associated with adherence including age, income, level of education, knowledge of disease and satisfaction with information about medicines.^{19 20} Several authors have suggested that patients' beliefs about medicines play an important role in medication adherence in chronic diseases.^{7 21–24} For example, in rheumatology, Neame and Hammond²¹ found that concerns about medicines were higher in non-adherent than adherent RA patients and were associated with feelings of helplessness. Patients with higher levels of concerns were those who reported more adverse effects from DMARDs. Also, disease severity plays a key role in patients' decisions to either take or not take their treatments.²⁵ However, few studies^{26 27} have investigated the role of ethnicity as a factor affecting medication adherence in patients with RA, particularly in South Asians. Garcia-Gonzalez *et al*²⁷ found that Hispanic and African American patients with RA had significantly reduced medication adherence when compared with patients of White origin. They attributed this to greater feelings of depression and the perception of medication as harmful in the minority

ethnic groups. Patients with a low level of education and less knowledge about their disease were less likely to take their medication. A pilot study by Kumar *et al*²⁸ did not measure adherence rates to medicines but did highlight that RA patients from a South Asian background had more negative beliefs about their medicines compared to White British patients. These negative beliefs were influenced by a range of factors including views about fate.²⁹ Furthermore, South Asian patients with RA have also been shown to be different in their help-seeking behaviours.³⁰ Patients' beliefs about the meaning of symptoms were important when deciding to seek medical help. This was sometimes related to a perception that their symptoms represented God's punishment and medical help seeking was thus often delayed, contributing towards delays in initiating treatment.³⁰ This study aims to assess the relationship between adherence to medicines and biopsychosocial variables (eg, age, gender, level of education, socioeconomic status, occupation, employment status and disease duration) in patients with RA of South Asian (defined as originating from India or Pakistan) and White British origin. Further, the study will explore the reasons underlying high and low adherence among these two groups of patients.

METHODS AND ANALYSIS

A two-phased mixed methods approach encompassing both quantitative and qualitative designs will be used.

Phase 1: quantitative survey

The valid and reliable Medication Adherence Report Scale (MARS)⁷ will be used to capture data to address the relationship between adherence to medicines used in RA and potential explanatory variables (identified from factors that are known to influence adherence)⁸ in patients with RA of White British and South Asian origin. MARS is a five-item self-report scale for assessment of non-adherent behaviour (eg, I forget to take them, and I alter the dose). The items are rated on a five-point Likert scale,⁷ ranging from 1=very often to 5=never.

BMQ will be used to measure beliefs about medicines. The BMQ assesses perceptions of medication necessity and perceived concerns about medicines.^{16 31} The specific treatment necessity (Necessity, score range from 5 to 25, higher score indicating a stronger need for medication) and treatment concerns (Concern, score range from 6 to 30, higher score indicating more concerns about medication) subscales measure personal evaluations of the benefits and costs of treatment. The BMQ General scale assesses patients' beliefs about the use of medicines and whether they are overprescribed by clinicians (Overuse, score range from 3 to 15). The Harm scale assesses patients' beliefs about the perceived risk of medicines being harmful and addictive (Harm, scores range from 5 to 25). In the assessment of Overuse and

Harm scales, higher scores indicate a more negative perception towards medication in general.

The Health Assessment Questionnaire (HAQ)³² and IPQ¹¹ have been validated and are already available in different languages,^{33 34} for example, Hindi. HAQ will be used to assess function as we have shown that patients with negative beliefs have worse function scores.²⁸ Thus, the association of HAQ with MARS may provide useful data. The Illness Perception tool¹¹ has five discrete attributes (identity, cause, timeline, consequences, cure and control) that patients tend to have about their condition (their illness perception). The scores range from a five-point scale, where 1=strongly disagree and 5=strongly agree). These help predict health behaviours such as medication adherence. Looking at the association between IPQ and MARS will be useful to determine associations with medication adherence.

Patient satisfaction with information can be measured using the Satisfaction with Information about Medications (SIMS) questionnaire.³⁵ This questionnaire has two subscales—action and usage of drugs (nine items), and potential problems (eight items). Those who report that the information is ‘about right’ or indicate ‘none needed’ will be classified as satisfied (scored 1). Those who report that the information is ‘too much’, ‘too little’ or indicate ‘none received’ will be classified as dissatisfied (scored 0). Responses will be recorded on a Likert scale (ie, too much–none needed). By capturing these data, we will be able to assess the relationship between SIMS and adherence in our study population. For the purposes of this study, the HAQ³² IPQ¹¹ BMQ¹⁶ SIMS questionnaire³⁵ and MARS⁷ will, for the first time, be independently audio translated into Hindi, Punjabi and Urdu followed by back translation to ensure linguistic validity.³⁶ This is because the study will take place in a largely multicultural city in which 18.5% of the population is of South Asian origin.³⁷ Furthermore, we have reported that about a third of the South Asian population attending rheumatology clinics in Birmingham required interpreters and about 33% of that population were not able to read the script of their preferred language.³⁸ Consequently, written translation of the questionnaires would exclude a sizeable proportion of potentially eligible individuals. To test the logistics of filling in the questionnaire, the translated audiotapes will be piloted among a group of patients.

Choice of questionnaires

The questionnaires were chosen based on their use in chronic diseases. MARS and BMQ have been used in patients with asthma, chronic obstructive pulmonary disease, diabetes and renal failure.¹⁶ In RA, Neame and Hammond²¹ have shown that the BMQ–concern scale distinguished between low and higher adherence (MARS), whereas the necessity scale was shown to be correlated with the number of DMARDs and adherence.

Patients usually require a rationale for their medication before following advice about taking it.³⁵ It is well known that 40% of patients on chronic medication do

not take their medication as prescribed. It is likely that medication adherence is improved if patients are provided with information which addresses the issues they want to know about in a way that is comprehensible. Patient satisfaction with information can be measured using the SIMS questionnaire.³⁵ This questionnaire has two subscales—action and usage of drugs (nine items) and potential problems (eight items). Those who report that the information is ‘about right’ or indicate ‘none needed’ will be classified as satisfied (scored 1). Those who report that the information is ‘too much’, ‘too little’ or indicate ‘none received’ will be classified as dissatisfied (scored 0). Responses will be recorded on a Likert scale (too much–none needed). By capturing these data, we will be able to assess the relationship between SIMS and adherence in our study population. Furthermore, SIMS has been shown to be consistent in patients with asthma, cardiac rehabilitation, diabetes and oncology.³⁵ It also distinguishes between low and high adherence in RA.³⁹

Also, IPQ has been used in a variety of conditions such as diabetes, hypertension and HIV.¹¹ Among RA patients, Hughes *et al*¹⁰ found that some of the IPQ domains were associated with low and high adherence. There are very few studies that provide evidence regarding illness perception among RA patients of South Asian origin. The illness perception tool has five discrete attributes (identity, cause, timeline, consequences, cure and control) that patients tend to have about their condition (their illness perception score ranging from a five-point scale, where 1=strongly disagree and 5=strongly agree). These help predict health behaviours such as medication adherence. For example, medication adherence in patients with hypercholesterolaemia has been shown to be related to beliefs that the disease has severe coronary consequences.^{41 42} Hypertensive patients who believe that their condition is chronic are more likely to adhere to their antihypertensive medication than those who believe it to be in an acute condition.^{41 42} The latter group of patients may view themselves as being cured. Looking at the association between IPQ and MARS will be useful to determine associations with medication adherence.

Finally, HAQ³² will be used to assess functional disability as our previous work has shown that patients with negative beliefs had a higher functional disability score. Thus, the association of HAQ with MARS may provide useful data. In addition, data on demographic variables (such as age, gender, ethnicity, level of education) and disease-related variables such as disease activity score Q13 (DAS28).⁴⁷ A free text box will be included to allow patients to record information on other variables which they feel may influence their adherence.

Patient engagement

Using BMQ to quantify adherence has the advantage that it will help embed the findings from this study within the Necessity–Concern Framework. However, before we made a final decision on which tool(s) to use

to measure adherence, the views of patients were sought.⁴³ The study design was presented to the rheumatology departmental patient User Group. An invitation to join the project Steering Group was offered to all patients, and four (two White British and two South Asian patients) joined this group. None of these patients' RA was being treated by the researchers from a clinical perspective. The most common methods of measuring adherence were discussed including patient questioning, patient logs, pill counts⁴⁴ and the widely used medication electronic monitoring system (MEMS).^{45 46} This system involves a cap that measures opening and closing as dosages are taken, and is able to report on the time and dates that the dosages were taken. The Steering Group strongly felt that the MEMS approach could have the potential to change the patients' behaviour and was thus not felt to be appropriate. Patients preferred a self-reported tool, such as MARS,⁷ which is phrased in a way that sanctions non-adherence. However, patients did acknowledge that by using this approach adherence might be over-reported by some patients.

Inclusion criteria

Patients with RA (according to the 1987 American College of Rheumatology criteria)⁴⁸ of either White British or South Asian origin will be invited to participate. Patients will be diagnosed with RA for at least 3 months; be 18 years or over; be taking at least one DMARD/have been on a DMARD in the past. Patients will be classified as being of White British origin if they had three or more grandparents who had been born in the UK and regard themselves as being of White origin. Patients will be classified as being of South Asian origin if they had three or more grandparents who had been born in India or Pakistan and regarded themselves as being of South Asian origin.

Recruitment

Patients will be recruited from three hospital-based Rheumatology clinics in Birmingham, UK (Sandwell and West Birmingham Hospitals NHS Trust, University Hospitals Birmingham NHS Foundation Trust and Heart of England NHS Foundation Trust).

Data and sample collection

Data will be collected by a researcher (KK) by questionnaires, clinical assessments and case notes review. The sample size of 176 (88 patients from each ethnic group) will detect with at least 80% power a significant Pearson correlation coefficient at the 5% level if the true significant correlation of adherence and beliefs about medicines is less than or equal to -0.21 or greater than or equal to $+0.21$. This calculation has been based on a previous study that investigated the relationship between beliefs about medicine and adherence.⁷ In this paper, the authors found a Pearson correlation coefficient of 0.21 between necessity score and adherence and

a Pearson correlation coefficient of -0.33 between concern score and adherence. Thus, the sample size will enable us to detect correlations of these magnitudes with at least 80% power. Data will be analysed by using the Statistical Package for Social Sciences and modelled to assess the relationship between adherence and the variables studied. The extent to which variation in adherence can be explained by the factors under investigation will be assessed.⁸ First, univariate analyses will be performed to test the association between the outcome (adherence to DMARDs) and potential explanatory variables in participants with RA. There will be two primary questions for the univariate analyses:

- ▶ Is the BMQ necessity score correlated with adherence?
- ▶ Is the BMQ concerns score correlated with adherence?

Second, general linear models with adherence to DMARDs as the dependent variable will be fitted, adjusting for age, sex, number of years of education, significant predictors on univariate analysis and clinically relevant factors such as disease duration, DAS28, HAQ scores and DMARDs that are commonly used to treat RA. Interactions with ethnicity will be examined and if an interaction with ethnicity is identified, all subsequent analysis will be stratified by ethnicity (South Asian vs White British).

Phase 2 indepth qualitative interviews

There will be two primary questions for the qualitative phase

- ▶ What factors motivate those with good adherence to adhere well?
- ▶ What strategies aid medication adherence in RA patients?

To obtain a wide representation of views about barriers to and facilitators of adherence, patients will be interviewed until theoretical saturation is reached. Patients will be identified from phase 1 with low adherence (defined as the lowest tertile on MARS) and higher levels of medication adherence (defined as the upper tertile on MARS) and invited for individual interviews. In each group (patients with good and poor adherence), there will be a mixture of White and South Asian patients. A semistructured interview schedule will be developed from the literature and with input from the Patient Steering Group. A maximum variety approach will be used to capture a broad social and demographic subject range.⁴⁹ Interviews will take place within the hospital in a non-clinical setting (eg, in the postgraduate centre in dedicated rooms for interviewing) to allow patients to talk freely about issues related to medication adherence.

Data analysis

Data collection and analysis will be iterative, occurring as data collection proceeds, with new data informing of subsequent interviews. The transcribed data will be analysed by using constant comparative analysis.⁴⁹ This process involves looking at the different patterns and

reflecting on them to seek similarities between emerging themes. Each transcript will be coded (labels) to capture the essence of the patients' narratives. By creating several labels, a structure of codes will be developed to understand the meaning of the data. The coding will be staged. During the coding, the researcher will look for demographic, factual (ie, disease symptoms) and/or conceptual meaning. For example, are some issues about medication adherence related to gender? Or what aspects of the patient's story help explain the meaning of medication adherence? The researcher will allow for spontaneous themes to emerge and, in addition, attention will be paid to more specific themes chosen from phase 1 of the study, which may help to explain patient adherence. A separate list of themes for each ethnic group will be compiled. The transcripts will be read and independently coded by two other members of the research team, a clinician (PG) and a medical sociologist (SG), to ensure an interdisciplinary perspective. Discussion will be held between the team to finalise themes for the coding.

Ethical approval and dissemination

This study has been approved by the South Birmingham (10/H1207/89) and Coventry and Warwickshire (12/WM/0041) Research Ethics Committees. Verbal and written consent will be obtained from all patients. For those whose first language is not English, the researcher (KK) will conduct an oral discussion about taking part in the study with patients in Hindi, Punjabi and Urdu. The authors will disseminate the findings in peer-reviewed publications.

SUMMARY

The aim of this study is to assess the relationship between adherence to medicines and biopsychosocial variables in RA patients of White British and South Asian backgrounds. Furthermore, it will explore the reasons underlying high and low adherence in these two ethnic groups.

Many studies to date have provided insight into approaches to improve the adherence in patients with chronic diseases.⁵⁰ A considerable amount of literature has reported a number of factors related to adherence.⁵¹ These include factors related to healthcare providers, medical systems, disease treatments, demographics and society.⁸ Furthermore, an emphasis has been given to cognitive models that focus on patients' perceptions and beliefs as motivating factors for adhering to therapy.^{7 13} Health beliefs, such as the perceived seriousness of the disease, fear of complications and the efficacy of treatment, can successfully predict better medication adherence levels.⁵² It has been documented that patients adhere well when the treatment regimen is manageable and makes sense to them, when it demonstrates efficiency, and when from their perspective the benefits outweigh the concerns.¹⁴ Such decision making is typically

based on individuals' subjective perceptions of the pros and cons of the therapy.⁵³ However, such issues have not been explored in patients with RA from the South Asian populations, and this study seeks to fill this gap in the literature. Importantly, this study will address two main issues. First, the study will extract characteristics that are associated with high and low adherence among RA patients and assess the impact of ethnicity on this. Second, the study will allow an opportunity to further explore issues that arise in phase 1 of the study using qualitative methodologies within phase 2. The motivational factors that encourage patients to adhere well will be discussed in more detail. Furthermore, this will provide information for the development of an intervention to change beliefs and behaviours.

Acknowledgements This study is funded by the National Institute for Health Research Doctoral Fellowship (KK) and Primary Care Clinical Sciences, is a member of the NIHR National School of Primary Care.

Contributors KK, KR, PG and SG conceived the idea of the study and were also responsible for its design. The initial draft of the manuscript was prepared by KK and PG and then circulated repeatedly among all authors (SG, KR, PN, KS and RH) for critical revision. KK is the guarantor of this paper.

Funding This study is funded by the National Institute for Health Research (NIHR) Grant number (RGKP15291).

Competing interests None.

Patient consent Obtained.

Ethics approval This study has been approved by the South Birmingham (10/H1207/89) and Coventry and Warwickshire (12/WM/0041) Research Ethics Committees.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES

- Emery P, Salmon M. Early rheumatoid arthritis: time to aim for remission? *Ann Rheum Dis* 1995;54:944–7.
- Emery P. Evidence supporting the benefit of early intervention in rheumatoid arthritis. *J Rheumatol* 2002;29:3–8.
- Young A, Dixey J, Kulinskaya E, et al. Which patients stop working because of rheumatoid arthritis? Results of five years' follow up in 732 patients from the Early RA Study (ERAS). *Ann Rheum Dis* 2002;61:335–40.
- Raza K. The Michael Mason prize: early rheumatoid arthritis—the window narrows. *Rheumatology (Oxford)* 2010;49:406–10.
- Raza K, Buckley CE, Salmon M, et al. Treating very early rheumatoid arthritis. *Best Pract Res Clin Rheumatol* 2006;20:849–63.
- Kitas GD, Gabriel SE. Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives. *Ann Rheum Dis* 2011;70:8–14.
- Horne R, Weinman J. Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. *J Psychosom Res* 1999;47:555–67.
- World Health Organization. *Adherence to long-term therapies—evidence for action*. Geneva, Switzerland: WHO Library Cataloguing-in-Publication Data, 2003:1–211.
- Harrold LR, Andrade SE. Medication adherence of patients with selected rheumatic conditions: a systematic review of the literature. *Semin Arthritis Rheum* 2009;38:396–402.
- Horne R, Weinman J. Self regulation and self management in asthma: exploring the role of illness perceptions and treatment beliefs in explaining non-adherence to preventer medication. *Psychol Health* 2002;17:17–32.
- Weinman J, Petrie KJ. Illness perceptions: a new paradigm for psychosomatics? *J Psychosom Res* 1997;42:113–16.
- Clifford S, Barber N, Horne R. Understanding different beliefs held by adherers, unintentional nonadherers, and intentional nonadherers: application of the Necessity-Concerns Framework. *J Psychosom Res* 2008;64:41–6.

13. Phatak HM, Thomas J. Relationships between beliefs about medications and nonadherence to prescribed chronic medications. *Ann Pharmacother* 2006;40:1737–42.
14. Horne R. Patients' beliefs about treatment: the hidden determinant of treatment outcome? *J Psychosom Res* 1999;47:491–5.
15. Horne R, Cooper V, Gellaity G, *et al.* Patients' perceptions of highly active antiretroviral therapy in relation to treatment uptake and adherence: the utility of the Necessity-Concerns framework. *J Acquir Immune Defic Syndr* 2007;45:334–41.
16. Horne R, Weinman J, Hankins M. The beliefs about Medicines Questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medicines. *Psychol Health* 1998;14:1–24.
17. Brus H, Van de LM, Taal E, *et al.* Determinants of compliance with medication in patients with rheumatoid arthritis: the importance of self-efficacy expectations. *Patient Educ Couns* 1999;36:57–64.
18. Wong M, Mulherin D. The influence of medication beliefs and other psychosocial factors on early discontinuation of disease-modifying anti-rheumatic drugs. *Musculoskelet Care* 2007;5:148–59.
19. Viller F, Guillemin F, Briancon S, *et al.* Compliance to drug treatment of patients with rheumatoid arthritis: a 3 year longitudinal study. *J Rheumatol* 1999;26:2114–22.
20. Park DC, Hertzog C, Leventhal H, *et al.* Medication adherence in rheumatoid arthritis patients: older is wiser. *J Am Geriatr Soc* 1999;47:172–83.
21. Neame R, Hammond A. Beliefs about medications: a questionnaire survey of people with rheumatoid arthritis. *Rheumatology (Oxford)* 2005;44:762–7.
22. Goodacre LJ, Goodacre JA. Factors influencing the beliefs of patients with rheumatoid arthritis regarding disease-modifying medication. *Rheumatology (Oxford)* 2004;43:583–6.
23. Treharne GJ, Lyons AC, Hale ED, *et al.* 'Compliance' is futile but is 'concordance' between rheumatology patients and health professionals attainable? *Rheumatology (Oxford)* 2006;45:1–5.
24. Treharne GJ, Lyons AC, Kitas GD. Adherence to medication. *N Engl J Med* 2005;353:1972–4.
25. Salt E, Peden A. The complexity of the treatment: the decision-making process among women with rheumatoid arthritis. *Qual Health Res* 2011;21:214–22.
26. Dunbar-Jacob J, Holmes JL, Sereika S, *et al.* Factors associated with attrition of African Americans during the recruitment phase of a clinical trial examining adherence among individuals with rheumatoid arthritis. *Arthritis Rheum* 2004;51:422–8.
27. Garcia-Gonzalez A, Richardson M, Garcia Popa-Lisseanu M, *et al.* Treatment adherence in patients with rheumatoid arthritis and systemic lupus erythematosus. *Clin Rheumatol* 2008;27:883–9.
28. Kumar K, Gordon C, Toescu V, *et al.* Beliefs about medicines in patients with RA and SLE: a comparison between patients of South Asian and White British origin. *Rheumatology* 2008;47:690–7.
29. Kumar K, Gordon C, Barry R, *et al.* 'It's like taking poison to kill poison but I have to get better': a qualitative study of beliefs about medicines in RA and SLE patients of South Asian origin. *Lupus* 2011;20:837–44.
30. Kumar K, Daley E, Khattak F, *et al.* The influence of ethnicity on the extent of, and reasons underlying, delay in general practitioner consultation in patients with RA. *Rheumatology (Oxford)* 2010;49:1005–12.
31. Menckeberg TT, Bouvy ML, Bracke M, *et al.* Beliefs about medicines predict refill adherence to inhaled corticosteroids. *J Psychosom Res* 2008;64:47–54.
32. Kirwan JR, Reeback JS. Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid-arthritis. *Br J Rheumatol* 1986;25:206–9.
33. Chogle AR, Mistry KJ, Deo SS. Comparison of the Indian version of Health Assessment Questionnaire Score and Short Form 36 Physical Function Score in rheumatoid arthritis using Rasch analysis. *Indian J Rheumatol* 2008;3:52–7.
34. Bean D, Cundy T, Petrie KJ. Ethnic differences in illness perceptions, self-efficacy and diabetes self-care. *Psychol Health* 2007;22:787–811.
35. Horne R, Hankins M, Jenkins R. The Satisfaction with Information about Medicines Scale (SIMS): a new measurement tool for audit and research. *Qual Health Care* 2001;10:135–40.
36. Koller M, Aaronson NK, Blazeby J, *et al.* Translation procedures for standardised quality of life questionnaires: the European Organisation for Research and Treatment of Cancer (EORTC) approach. *Eur J Cancer* 2007;43:1810–20.
37. Scott A, Pearce D, Goldblatt P (Office for National Statistics). The sizes and characteristics of the minority ethnic population of Great Britain—latest estimates. *Popul Trends* 2001;105:6–10.
38. Kumar K, Deeming A, Gordon C, *et al.* Experience with a Punjabi, Urdu and Hindi rheumatology telephone helpline. *Musculoskelet Care* 2009;7:210–18.
39. Van den Bemt BJ, Zwikker HE, Van den Ende CH. Medication adherence in patients with rheumatoid arthritis: a critical appraisal of the existing literature. *Expert Rev Clin Immunol* 2012;8:337–51.
40. Hughes LD, Done J, Young A. Patients that report high adherence to DMARDs show higher perceptions of serious consequences and negative emotional response to rheumatoid arthritis than patients with low self reported adherence. *Ann Rheum Dis* 2011;70:760.
41. Patel RP, Taylor SD. Factors affecting medication adherence in hypertensive patients. *Ann Pharmacother* 2002;36:40–5.
42. Lip GY, Khan H, Bhatnagar A, *et al.* Ethnic differences in patient perceptions of heart failure and treatment: the West Birmingham heart failure project. *Heart* 2004;90:1016–19.
43. Stewart DC. Making the difference: actively involving patients, carers and the public. *Natl Inst Health Res* 2011.
44. Hill J, Bird H, Johnson S. Effect of patient education on adherence to drug treatment for rheumatoid arthritis: a randomised controlled trial. *Ann Rheum Dis* 2001;60:869–75.
45. Balkrishnan R, Carroll CL, Camacho FT, *et al.* Electronic monitoring of medication adherence in skin disease: results of a pilot study. *J Am Acad Dermatol* 2003;49:651–4.
46. Shi L, Liu J, Koleva Y, *et al.* Concordance of adherence measurement using self-reported adherence questionnaires and medication monitoring devices. *Pharmacoeconomics* 2010;28:1097–107.
47. Felson DT, Anderson J, Boers M, *et al.* The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. *Arthritis Rheum* 1993;36:729–40.
48. Arnett FC, Edworthy SM, Bloch DA, *et al.* The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum* 1988;31:315–24.
49. Greenhalgh T, Taylor R. Papers that go beyond numbers (qualitative research). *BMJ* 1997;315:740–3.
50. Osterberg L, Terrence B. Adherence to medication. *N Engl J Med* 2005;353:487–97.
51. Delamater AM. Improving patient adherence. *Clin Diabetes* 2006;24:71–7.
52. Hayes RP, Bowman L, Monahan PO, *et al.* Understanding diabetes medications from the perspective of patients with type 2 diabetes: prerequisite to medication concordance. *Diabetes Educ* 2006;32:404–14.
53. Cameron LD, Leventhal H. *The Self-regulation of health and illness behaviour*. London: Routledge, 2003:337.